Mereo BioPharma Group plc (MREO)
NASDAQ: MREO · Real-Time Price · USD
4.010
-0.270 (-6.31%)
At close: Nov 4, 2024, 4:00 PM
4.100
+0.090 (2.24%)
Pre-market: Nov 5, 2024, 8:10 AM EST
Mereo BioPharma Group Stock Forecast
Stock Price Forecast
The 4 analysts with 12-month price forecasts for MREO stock have an average target of 7.50, with a low estimate of 7.00 and a high estimate of 8.00. The average target predicts an increase of 87.03% from the current stock price of 4.01.
Analyst Consensus: Strong Buy
* Price targets were last updated on Oct 1, 2024.
Analyst Ratings
The average analyst rating for MREO stock from 4 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | May '24 | Jun '24 | Jul '24 | Aug '24 | Sep '24 | Oct '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Buy | 1 | 3 | 3 | 3 | 3 | 3 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 4 | 4 | 4 | 4 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates $7 | Buy | Reiterates | $7 | +74.56% | Oct 1, 2024 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates $7 | Buy | Reiterates | $7 | +74.56% | Sep 16, 2024 |
| Needham | Needham | Strong Buy Reiterates $7 | Strong Buy | Reiterates | $7 | +74.56% | Aug 13, 2024 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates $7 | Buy | Reiterates | $7 | +74.56% | Jul 22, 2024 |
| Leerink Partners | Leerink Partners | Buy Maintains $6 → $8 | Buy | Maintains | $6 → $8 | +99.50% | Jun 20, 2024 |
Financial Forecast
Revenue This Year
11.64M
from 10.00M
Increased by 16.39%
Revenue Next Year
12.74M
from 11.64M
Increased by 9.44%
EPS This Year
-0.02
from -0.22
EPS Next Year
-0.02
from -0.02
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 59.9M | 36.8M | 148.5M | ||
| Avg | 11.6M | 12.7M | 69.1M | ||
| Low | n/a | n/a | 1.0M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 499.1% | 215.9% | 1,065.4% | ||
| Avg | 16.4% | 9.4% | 442.4% | ||
| Low | - | - | -92.0% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 0.05 | -0.01 | -0.02 | ||
| Avg | -0.02 | -0.02 | -0.02 | ||
| Low | -0.05 | -0.04 | -0.02 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.